SCM
GENB icon

Silverarc Capital Management’s Generate Biomedicines GENB Stock Holding History

Silverarc Capital Management’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$1.25M – 98
2026
Q1 		$1.25M Buy
+100,000
New +$1.22M 0.13% 66

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Silverarc Capital Management's GENB Position: Q2 2026 in Review

Silverarc Capital Management sold out of Generate Biomedicines (GENB) in Q2 2026, closing a stake of 100,000 shares — an estimated $1.25M sold.

Silverarc Capital Management first reported a position in GENB in Q1 2026 and held it in 1 quarter. The position peaked at $1.25M in Q1 2026. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Silverarc Capital Management reported no remaining Generate Biomedicines position as of Q2 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 100,000 Generate Biomedicines shares in Q2 2026, an estimated $1.25M.
  • Silverarc Capital Management first reported a position in Generate Biomedicines in Q1 2026 and held it in 1 quarter.
  • Silverarc Capital Management's Generate Biomedicines position peaked at $1.25M in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.